MedTrace Logo

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

NCT06682780 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2025-09-25

No results posted yet for this study

Summary

This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

LM-2417

Q2W/Q3W,Intravenous Drip

DRUG

Docetaxel

Q3W,Intravenous Drip

DRUG

Toripalimab/Tirelizumab

Q3W,Intravenous Drip

DRUG

Carboplatin

Q3W,Intravenous Drip

DRUG

Niraparib

QD,Oral Administration

DRUG

Lenvatinib

QD,Oral Administration

Sponsors & Collaborators

  • LaNova Medicines Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-17
Primary Completion
2028-12-25
Completion
2029-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06682780 on ClinicalTrials.gov